Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

130.59 +1.33 (+1.03%)

Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

50 51 Next >

Boston Scientific's Farapulse Eyes Stronger US Market Position With Potential FDA Approval ↗

August 11, 2023

Boston Scientific Corp (NYSE: BSX) will present results from ADVENT pivotal trial for its Farapulse Pulsed Field Ablation (PFA) system at the 2023 European Society of Cardiology Congress on 27 August....

Via Benzinga

How Is The Market Feeling About Abbott Laboratories? ↗

August 10, 2023

Via Benzinga

Is Abbott Laboratories Stock a Buy Now? ↗

August 10, 2023

The healthcare company recently boosted its guidance.

Via The Motley Fool

Is AbbVie Still a Good Dividend Stock to Buy? ↗

August 08, 2023

Find out if AbbVie can overcome sinking sales of its top-selling product.

Via The Motley Fool

2 Top Stocks to Buy in August and Hold Forever ↗

August 06, 2023

These companies won't disappoint long-term investors.

Via The Motley Fool

This Is What Whales Are Betting On Abbott Laboratories ↗

August 04, 2023

Via Benzinga

Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years ↗

July 31, 2023

Via Benzinga

Looking Into Abbott Laboratories's Recent Short Interest ↗

July 25, 2023

Via Benzinga

Looking At Abbott Laboratories's Recent Unusual Options Activity ↗

July 20, 2023

Via Benzinga

Does Abbott Laboratories' Dividend Make It a Buy? ↗

August 04, 2023

There's a lot to like about this business when it comes to dividends.

Via The Motley Fool

Glucose Monitor Maker DexCom In Buy Zone After Gapping Higher

July 31, 2023

Strong Q2 earnings performance propelled DexCom higher. Investors cheered the glucose monitoring leader's bullish sales view and international expansion plans.

Via MarketBeat

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 28, 2023

Via Benzinga

Dexcom Earnings Tops Estimates, Medical Device Maker Hikes Outlook ↗

July 27, 2023

Dexcom stock rose after the company reported Q2 earnings and revenue that topped Wall Street targets and raised full-year sales guidance.

Via Investor's Business Daily

Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform – Insights From The Discussion ↗

July 27, 2023

Chronic back pain is a significant issue in the United States, affecting millions of individuals annually.

Via Benzinga

Abbott Laboratories (ABT) Q2 2023 Earnings Call Transcript ↗

July 20, 2023

ABT earnings call for the period ending June 30, 2023.

Via The Motley Fool

Abbott Stock Edges Higher As Earnings Decline But Still Top Forecasts ↗

July 20, 2023

The company continues to expect some Covid sales this year, but cut its outlook.

Via Investor's Business Daily

Abbott Recalls Amplatzer Steerable Delivery Sheath On Risk Of Air Embolism ↗

July 26, 2023

Abbott Laboratories (NYSE: ABT) is recalling the Amplatzer Steerable Delivery Sheath due to an increased

Via Benzinga

2 Top Dividend Stocks to Buy and Hold Forever ↗

July 25, 2023

They have been paying dividends for a long time.

Via The Motley Fool

Russia Is Seizing European Company Assets — What US Businesses Are Still At Risk? ↗

July 24, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 24, 2023

Via Benzinga

3 Ultrareliable Dividend Stocks to Buy and Hold for Decades ↗

July 24, 2023

These stocks have decades of annual dividend raises under their belts, and rising healthcare costs mean there could be plenty more to come.

Via The Motley Fool

Apple To Rally Over 17%? Here Are 10 Other Analyst Forecasts For Monday ↗

July 24, 2023

Citigroup raised the price target for Cintas Corporation (NASDAQ: CTAS) from $540 to $550. Citigroup analyst Leo Carrington downgraded the stock from Buy to Neutral. Cintas shares fell 0.8% to $503.43...

Via Benzinga

Abbott's Higher Than Expected Q2 Earnings: Analyst Foresees Strong Performance In 2024 ↗

July 21, 2023

Thursday, Abbott Laboratories (NYSE: ABT) reported better-than-expected Q2 earnings.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 ↗

July 21, 2023

Via Benzinga

Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review ↗

July 21, 2023

But all the major indexes are at or near 15-month highs.

Via Investor's Business Daily

J&J, Abbott Labs And JPM Among Jim Cramer's Top Picks As Market Shifts Focus From Tech ↗

July 21, 2023

Via Benzinga

Johnson & Johnson's Inflection Point: What it Means for Investors

July 20, 2023

Johnson & Johnson stock and the company show signs of strength and growth while offering value and yield relative to its peer Abbott Laboratories.

Via MarketBeat

Abbott Laboratories Has the Prescription for Higher Share Prices

July 20, 2023

Abbott Laboratories stock is ready to rebound after a year of correction. The decline of COVID is priced into the market, and organic growth is accelerating.

Via MarketBeat

Tesla Recalls Over 17K EVs Over Camera & Seat Belt Issues, University Research Uncovers Unexpected Fluctuations In ChatGPT Capabilities, Juul Seeks FDA Nod For Next-Generation Vaporizer: Today's Top Stories ↗

July 20, 2023

Benzinga Tesla Recalls More Than 17,000 EVs Over Camera, Seat Belt Issues

Via Benzinga

Abbott Laboratories Clocks Strong Q2 Growth In Underlying Base Business, Reaffirms FY23 Outlook ↗

July 20, 2023

Abbott Laboratories (NYSE: ABT) has reported Q2 FY23 adjusted EPS of $1.08, down 25% Y/Y, beating the consensus of $1.05.

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

50 51 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Abbott Laboratories (NY:ABT)

All News about Abbott Laboratories

Starting at $3.75/week.

Subscribe Today